Drugs Affecting Blood and Blood Formation Practice Questions

Q: What is the most common adverse effect associated with ticlopidine?

Diarrhea. **Explanation:** Ticlopidine is a first-generation P2Y12 receptor antagonist (thienopyridine) that inhibits ADP-induced platelet aggregation. **1. Why Diarrhea is the correct answer:** While ticlopidine is notorious for its hematological toxicities, **diarrhea** is statistically the **most common** adverse effect, occurring in approximately 12–20% of patients. It is often dose-dependent and typically occurs within the first few weeks of treatment. Other frequent gastrointestinal disturbances include nausea and dyspepsia. **2. Analysis of Incorrect Options:** * **Neutropenia (Option A):** This is the most **serious** and characteristic side effect, occurring in about 2.4% of patients (severe in 0.8%). Because it can be life-threatening, it requires mandatory CBC monitoring every two weeks for the first three months. However, it is less frequent than diarrhea. * **Hemorrhage (Option C):** While bleeding is a risk with any antiplatelet agent, it is not the most common side effect specific to ticlopidine compared to GI upset. * **Thrombocytopenic Purpura (TTP) (Option D):** Ticlopidine is associated with rare but severe TTP. While high-yield for exams due to its severity, its incidence is very low (approx. 1 in 2,000 to 5,000 patients). **NEET-PG High-Yield Pearls:** * **Mechanism:** Irreversible blockade of P2Y12 (ADP) receptors. * **Clinical Shift:** Ticlopidine has been largely replaced by **Clopidogrel** because clopidogrel has a better safety profile (lower risk of neutropenia and TTP) and fewer GI side effects. * **Monitoring:** If ticlopidine is used, frequent monitoring of WBC counts is essential during the first 90 days. * **Pro-drug:** Like clopidogrel, ticlopidine is a pro-drug requiring hepatic activation.

Q: Which of the following is the mechanism of action of Pentasaccharide?

Factor Xa inhibition. **Explanation:** **Pentasaccharide (Fondaparinux)** is a synthetic anticoagulant that represents the minimum sequence of heparin required to bind to Antithrombin III. 1. **Mechanism of Action (Why B is correct):** Fondaparinux binds selectively and reversibly to **Antithrombin III (AT-III)**. This binding induces a conformational change in AT-III, which significantly increases its affinity for **Factor Xa**. Once bound, AT-III neutralizes Factor Xa, thereby inhibiting the conversion of prothrombin to thrombin and halting the coagulation cascade. Unlike Heparin, the pentasaccharide chain is too short to bridge AT-III to Thrombin (Factor IIa); therefore, it has **zero activity against Thrombin.** 2. **Analysis of Incorrect Options:** * **Option A & D:** These describe the action of **Unfractionated Heparin (UFH)**. UFH has a long polysaccharide chain (>18 units) that allows it to inhibit both Factor Xa and Thrombin (IIa) in a 1:1 ratio. * **Option C:** This is factually incorrect. Pentasaccharide is an **Antithrombin activator/agonist**, not an inhibitor. It utilizes Antithrombin to achieve its effect. **High-Yield Clinical Pearls for NEET-PG:** * **HIT Safety:** Fondaparinux does not bind to Platelet Factor 4 (PF4); therefore, it carries a negligible risk of **Heparin-Induced Thrombocytopenia (HIT)**. * **Monitoring:** Unlike UFH, it does not require routine aPTT monitoring due to its predictable pharmacokinetics. * **Elimination:** It is excreted unchanged by the kidneys; thus, it is **contraindicated in severe renal failure** (CrCl <30 mL/min). * **Antidote:** There is no specific reversal agent (Protamine sulfate does not work for Fondaparinux).

Q: Which of the following is a low molecular weight heparin?

Enoxaparin. **Explanation:** **Correct Answer: B. Enoxaparin** Low Molecular Weight Heparins (LMWHs) are derived from Unfractionated Heparin (UFH) through enzymatic or chemical depolymerization. **Enoxaparin** is the most commonly used LMWH. Unlike UFH, which inhibits both Factor Xa and Thrombin (IIa) equally (1:1 ratio), LMWHs have a higher selectivity for **Factor Xa** (ratio 3:1). They offer several clinical advantages, including better bioavailability, a longer half-life, and a predictable dose-response that eliminates the need for routine aPTT monitoring. **Analysis of Incorrect Options:** * **A & D. Hirudin and Lepirudin:** These are **Direct Thrombin Inhibitors (DTIs)**. Hirudin is a natural anticoagulant derived from leech saliva, while Lepirudin is its recombinant analog. They act independently of Antithrombin III, making them the drugs of choice for patients with Heparin-Induced Thrombocytopenia (HIT). * **C. Tranexamic acid:** This is an **Antifibrinolytic** agent. It works by competitively inhibiting the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. It is used to control excessive bleeding, not as an anticoagulant. **High-Yield NEET-PG Pearls:** * **Examples of LMWHs:** Enoxaparin, Dalteparin, Reviparin, Nadroparin, and Tinzaparin. * **Monitoring:** While routine monitoring isn't required, **Factor Xa assay** is used if monitoring is necessary (e.g., in renal failure or pregnancy). * **Antidote:** Protamine sulfate partially neutralizes LMWHs (only about 60-75% effective compared to 100% for UFH). * **Elimination:** LMWHs are primarily excreted **renally**; thus, they are contraindicated in severe renal failure (CrCl <30 ml/min), where UFH remains the preferred choice.

Q: Which of the following is a glycoprotein IIb/IIIa receptor antagonist?

Abciximab. The **Glycoprotein (GP) IIb/IIIa receptor** is the final common pathway for platelet aggregation. When activated, these receptors bind to fibrinogen, forming cross-links between adjacent platelets to create a platelet plug [5]. **Why Abciximab is Correct:** **Abciximab** is a chimeric monoclonal antibody that binds irreversibly to the GP IIb/IIIa receptor, preventing fibrinogen binding and subsequent platelet aggregation [1]. Other drugs in this class include **Eptifibatide** (a cyclic peptide) and **Tirofiban** (a non-peptide small molecule) [1], [2]. These are potent antiplatelet agents typically used in Acute Coronary Syndrome (ACS) and during Percutaneous Coronary Intervention (PCI) [1]. **Analysis of Incorrect Options:** * **Clopidogrel & Ticlopidine:** These belong to the **P2Y12 receptor antagonists** (Thienopyridines). They work by inhibiting the ADP-induced pathway of platelet activation, which is upstream of the GP IIb/IIIa receptor [4]. * **Tranexamic acid:** This is an **Antifibrinolytic** agent. It works by inhibiting the conversion of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots [3]. It is used to control bleeding, not as an antiplatelet. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** GP IIb/IIIa inhibitors are the most potent antiplatelets because they block the "final common pathway." * **Abciximab Side Effect:** It can cause significant **thrombocytopenia**; platelet counts should be monitored [1]. * **Route:** All GP IIb/IIIa inhibitors are administered **intravenously** [2]. * **Antidote:** For Abciximab, the effect is long-lasting; if life-threatening bleeding occurs, a **platelet transfusion** is required [1].

Q: Which of the following is NOT an advantage of low molecular weight heparin over unfractionated heparin?

Higher efficacy in arterial thrombosis. **Explanation:** The correct answer is **A. Higher efficacy in arterial thrombosis.** Low Molecular Weight Heparins (LMWHs) like Enoxaparin and Dalteparin are derived from Unfractionated Heparin (UFH) but have different pharmacokinetic and pharmacodynamic profiles [1]. Crucially, **both UFH and LMWH have similar efficacy** in treating and preventing thromboembolic disorders [5]. Neither is superior to the other specifically for arterial thrombosis; in fact, UFH is often preferred in acute coronary syndromes requiring percutaneous intervention due to its shorter half-life and easy reversibility [3]. **Analysis of Incorrect Options:** * **B. Less frequent dosing:** LMWH has a longer half-life (4–6 hours) compared to UFH (1–2 hours). This allows for once or twice-daily subcutaneous dosing, whereas UFH often requires continuous infusion or frequent injections [3]. * **C. Higher and more consistent bioavailability:** LMWH binds less to plasma proteins and endothelial cells [1]. This results in superior subcutaneous bioavailability (~90% for LMWH vs. ~20-30% for UFH) and a more predictable dose-response. * **D. Laboratory monitoring not required:** Due to the predictable response, routine monitoring of aPTT is not required for LMWH [4]. Monitoring (Anti-Xa levels) is only reserved for special populations like obese patients, pregnant women, or those with renal failure [4]. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** UFH inhibits both Factor Xa and IIa (Thrombin) in a 1:1 ratio. LMWH primarily inhibits Factor Xa (ratio of Xa:IIa is 3:1) [2]. * **HIT Risk:** LMWH has a significantly lower risk of Heparin-Induced Thrombocytopenia (HIT) compared to UFH. * **Reversibility:** Protamine sulfate completely neutralizes UFH but only partially neutralizes LMWH. * **Elimination:** LMWH is excreted **renally**; therefore, it is contraindicated in chronic kidney disease (where UFH is the drug of choice) [4].

Q: Filgrastim is used for the treatment of which condition?

Neutropenia. **Explanation:** **Filgrastim** is a recombinant human **Granulocyte Colony-Stimulating Factor (G-CSF)**. It acts by binding to specific receptors on myeloid progenitor cells in the bone marrow, stimulating the proliferation, differentiation, and activation of **neutrophils**. * **Why Option A is Correct:** Filgrastim is primarily used to treat **Neutropenia** (low neutrophil count). It is the drug of choice for reducing the duration and severity of neutropenia in patients receiving myelosuppressive chemotherapy, those undergoing bone marrow transplantation, or patients with severe chronic neutropenia. By increasing the Absolute Neutrophil Count (ANC), it significantly reduces the risk of life-threatening infections. * **Why Other Options are Incorrect:** * **B. Anemia:** This is a deficiency of red blood cells (RBCs). It is treated with Erythropoiesis-Stimulating Agents (ESAs) like **Erythropoietin** or Darbepoetin, not G-CSF. * **C. Polycythemia:** This is an abnormal increase in RBCs. Treatment usually involves phlebotomy or myelosuppressive agents (e.g., Hydroxyurea); Filgrastim would worsen a high cell count. * **D. Neutrophilia:** This refers to an abnormally high neutrophil count. Filgrastim *causes* neutrophilia as a pharmacological effect; it is never used to treat it. **High-Yield Clinical Pearls for NEET-PG:** 1. **Side Effects:** The most common side effect of Filgrastim is **medullary bone pain** (due to marrow expansion). 2. **Sargramostim:** Unlike Filgrastim (G-CSF), Sargramostim is a **GM-CSF** (Granulocyte-Macrophage CSF) which stimulates neutrophils, monocytes, and eosinophils. 3. **Pegfilgrastim:** A pegylated form of Filgrastim with a much longer half-life, allowing for once-per-chemotherapy cycle dosing. 4. **Stem Cell Harvest:** Filgrastim is also used to mobilize hematopoietic stem cells into the peripheral blood for collection prior to autologous transplantation.

Q: Peginesatide is

An erythropoietin receptor agonist. **Peginesatide** is a synthetic, PEGylated peptide-based **erythropoietin receptor agonist** [1, 2]. Unlike recombinant erythropoietin (Epoetin alfa), it does not share structural homology with endogenous erythropoietin. It works by binding to and activating the erythropoietin receptor on erythroid progenitor cells in the bone marrow, thereby stimulating erythropoiesis [2, 3]. It was primarily developed for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. **Analysis of Incorrect Options:** * **Option A (IL-11 analogue):** **Oprelvekin** is the recombinant form of Interleukin-11. It is used to stimulate megakaryocytopoiesis to prevent severe thrombocytopenia following chemotherapy. * **Option C (G-CSF analogue):** **Filgrastim** and **Pegfilgrastim** are Granulocyte Colony-Stimulating Factor analogues used to treat neutropenia by stimulating the production of neutrophils [2]. * **Option D (GM-CSF analogue):** **Sargramostim** is a Granulocyte-Macrophage Colony-Stimulating Factor analogue that stimulates the production of neutrophils, eosinophils, and monocytes/macrophages. **High-Yield Clinical Pearls for NEET-PG:** * **Unique Structure:** Because Peginesatide has a different amino acid sequence than erythropoietin, it does not cross-react with anti-erythropoietin antibodies. This made it a potential candidate for treating **Pure Red Cell Aplasia (PRCA)** caused by such antibodies. * **FDA Status:** Although effective, Peginesatide was voluntarily withdrawn from the market shortly after its approval due to reports of severe, life-threatening **anaphylactic reactions** during the first dose. * **Dosing Advantage:** Due to PEGylation, it has a long half-life, allowing for once-monthly administration [2].

Q: Which one of the following preferentially activates plasminogen bound to fibrin and avoids the systemic lytic state?

Alteplase. **Explanation** The correct answer is **Alteplase (Option D)**. **1. Why Alteplase is Correct:** Alteplase is a recombinant **Tissue Plasminogen Activator (tPA)**. The fundamental pharmacological property that distinguishes it from older thrombolytics is its **"fibrin specificity."** Alteplase has a high affinity for plasminogen that is already bound to a fibrin clot. It converts this clot-bound plasminogen into active plasmin, leading to localized thrombolysis. Because it has low affinity for free-circulating plasminogen, it minimizes the systemic conversion of plasminogen to plasmin, thereby reducing the "systemic lytic state" and the associated risk of generalized bleeding. **2. Why Other Options are Incorrect:** * **Streptokinase (A):** This is a non-fibrin-specific thrombolytic derived from Beta-hemolytic Streptococci. It binds to both circulating and clot-bound plasminogen equally, leading to massive systemic depletion of fibrinogen and a high risk of systemic hemorrhage. * **Aminocaproic acid (B) & Tranexamic acid (C):** These are **antifibrinolytics**. They inhibit plasminogen activation and are used to *treat* excessive bleeding (e.g., in overdose of thrombolytics), not to induce clot lysis. **3. NEET-PG High-Yield Pearls:** * **Fibrin-Specific Agents:** Alteplase, Reteplase, and Tenecteplase (Tenecteplase is the most fibrin-specific and has the longest half-life, allowing bolus dosing). * **Non-Specific Agents:** Streptokinase and Urokinase. * **Antidote for Thrombolytics:** If life-threatening bleeding occurs, use Epsilon-aminocaproic acid (EACA) or Tranexamic acid. * **Clinical Note:** Despite fibrin specificity, all thrombolytics still carry a risk of intracranial hemorrhage.

Q: Which of the following is true regarding clopidogrel when compared to ticlopidine?

Clopidogrel is less likely to cause neutropenia.. **Explanation:** Both Clopidogrel and Ticlopidine are **P2Y12 receptor antagonists** (thienopyridines) that inhibit ADP-induced platelet aggregation. While they share the same mechanism of action, their side effect profiles differ significantly. **1. Why Option B is Correct:** Ticlopidine is associated with severe hematological toxicities, most notably **life-threatening neutropenia** (occurring in ~1% of patients) and agranulocytosis. It requires frequent monitoring of complete blood counts (CBC) during the first three months of therapy. **Clopidogrel**, a second-generation thienopyridine, was developed specifically to improve safety; it has a much lower incidence of bone marrow suppression and neutropenia, making it the preferred clinical choice. **2. Why the Other Options are Incorrect:** * **Option A:** Neither drug is typically associated with the formation of antiplatelet antibodies. This mechanism is more characteristic of Heparin-Induced Thrombocytopenia (HIT). * **Option C:** Clopidogrel does not inherently cause more severe bleeding than ticlopidine; both carry a similar risk of hemorrhage as a consequence of their antiplatelet action. * **Option D:** At standard clinical doses, both drugs provide comparable levels of maximal platelet inhibition. The primary advantage of clopidogrel is its **safety profile**, not superior efficacy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Both are **irreversible** inhibitors of the P2Y12 ADP receptor. * **Metabolism:** Clopidogrel is a **prodrug** activated by the hepatic enzyme **CYP2C19**. Genetic polymorphisms in CYP2C19 or concurrent use of **Omeprazole** (a CYP2C19 inhibitor) can reduce its clinical efficacy. * **Ticlopidine Side Effects:** Neutropenia, TTP (Thrombotic Thrombocytopenic Purpura), and severe GI upset. * **Prasugrel/Ticagrelor:** Newer agents that are more potent and have a faster onset of action than clopidogrel.

Question 1

What is the most common adverse effect associated with ticlopidine?

Accepted Answer

Diarrhea

Answer

Neutropenia

Answer

Hemorrhage

Answer

Thrombocytopenic purpura

Question 2

Which of the following is the mechanism of action of Pentasaccharide?

Accepted Answer

Factor Xa inhibition

Answer

Factor Xa inhibition and Thrombin inhibition

Answer

Antithrombin inhibitor

Answer

Thrombin inhibition

Question 3

Which of the following is a low molecular weight heparin?

Accepted Answer

Enoxaparin

Answer

Hirudin

Answer

Tranexamic acid

Answer

Lepirudin

Question 4

Which of the following is a glycoprotein IIb/IIIa receptor antagonist?

Accepted Answer

Abciximab

Answer

Clopidogrel

Answer

Tranexamic acid

Answer

Ticlopidine

Question 5

Which of the following is NOT an advantage of low molecular weight heparin over unfractionated heparin?

Accepted Answer

Higher efficacy in arterial thrombosis

Answer

Less frequent dosing

Answer

Higher and more consistent subcutaneous bioavailability

Answer

Laboratory monitoring of response not required

Question 6

Filgrastim is used for the treatment of which condition?

Accepted Answer

Neutropenia

Answer

Anemia

Answer

Polycythemia

Answer

Neutrophilia

Question 7

Peginesatide is

Accepted Answer

An erythropoietin receptor agonist

Answer

An IL-11 analogue

Answer

A G-CSF analogue

Answer

A GM-CSF analogue

Question 8

Which one of the following preferentially activates plasminogen bound to fibrin and avoids the systemic lytic state?

Accepted Answer

Alteplase

Answer

Streptokinase

Answer

Aminocaproic acid

Answer

Tranexamic acid

Question 9

Which of the following is true regarding clopidogrel when compared to ticlopidine?

Accepted Answer

Clopidogrel is less likely to cause neutropenia.

Answer

Clopidogrel is more likely to cause formation of antiplatelet antibodies.

Answer

Clopidogrel is more likely to cause severe bleeding.

Answer

Clopidogrel has a greater antiplatelet effect.

Question 10

True about iron administration?

Accepted Answer

Iron-dextran is not excreted.

Answer

Iron-sorbitol-citric acid is given intravenously.

Answer

Iron-dextran binds to transferrin.

Answer

Iron-dextran has a low molecular weight.

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?